Marcel Schmutz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marcel Schmutz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alina-Mariuca Marinescu
Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich
1 shared publication Clara Bekemeier
Institute of Animal Welfare Animal Behavior and Laboratory Animal Science School of Veterinary Medicine Freie Universitat Berlin, Berlin, Germany
1 shared publicationFabienne K. Roessler
Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH, Zurich, Switzerland
1 shared publication- Johannes Bohacek
Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich
1 shared publication - Justine Leonardi
Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH, Zurich, Switzerland
1 shared publication - Katharina Hohlbaum
German Centre for the Protection of Laboratory Animals (Bf3R), German Federal Institute for Risk Assessment (BfR), Berlin, Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 5 March 2026
- Published by Springer Nature in Lab Animal
- Vol. 55 (4) , 137-146
GrimACE: automated, multimodal cage-side assessment of pain and well-being in mice
Pain and welfare monitoring is essential for ethical animal testing, but current cage-side assessments are qualitative and subjective. Here we present the GrimACE, a fully standardized and automated cage-side monitoring tool for mice, the most widely used animals in research. The GrimACE uses computer vision to provide automated mouse grimace scale (MGS) assessment together with pose estimation in a safe, dark environment. We validated the system by analyzing pain after brain surgeries (craniotomies) with head implants under two analgesia regimes. Human-expert and automated MGS scores showed very high correlation (Pearson’s r = 0.87). Both expert and automated scores revealed that a moderate increase in pain can be detected for up to 48 h after surgeries, but that both a single dose of meloxicam (5 mg/kg subcutaneuously) or three doses of buprenorphine (0.1 mg/kg) + meloxicam (5 mg/kg subcutaneuously) provide adequate and comparable pain management. Simultaneous pose estimation demonstrated that mice receiving buprenorphine + meloxicam showed increased movement 4 h after surgery, indicative of hyperactivity, a well-known side effect of opioid treatment. Significant weight loss was also detected in the buprenorphine + meloxicam treatment group compared with the meloxicam-only group. In addition, detailed BehaviorFlow analysis and automated MGS scoring of control animals suggests that habituation to GrimACE is unnecessary, and that measurements can be repeated multiple times, ensuring standardized postoperative recovery monitoring.
- 5 March 2026
- Published by Springer Nature in Lab Animal
- Vol. 55 (4) , 137-146
Top Cited PapersOpen AccessGrimACE: automated, multimodal cage-side assessment of pain and well-being in mice
Pain and welfare monitoring is essential for ethical animal testing, but current cage-side assessments are qualitative and subjective. Here we present the GrimACE, a fully standardized and automated cage-side monitoring tool for mice, the most widely used animals in research. The GrimACE uses computer vision to provide automated mouse grimace scale (MGS) assessment together with pose estimation in a safe, dark environment. We validated the system by analyzing pain after brain surgeries (craniotomies) with head implants under two analgesia regimes. Human-expert and automated MGS scores showed very high correlation (Pearson’s r = 0.87). Both expert and automated scores revealed that a moderate increase in pain can be detected for up to 48 h after surgeries, but that both a single dose of meloxicam (5 mg/kg subcutaneuously) or three doses of buprenorphine (0.1 mg/kg) + meloxicam (5 mg/kg subcutaneuously) provide adequate and comparable pain management. Simultaneous pose estimation demonstrated that mice receiving buprenorphine + meloxicam showed increased movement 4 h after surgery, indicative of hyperactivity, a well-known side effect of opioid treatment. Significant weight loss was also detected in the buprenorphine + meloxicam treatment group compared with the meloxicam-only group. In addition, detailed BehaviorFlow analysis and automated MGS scoring of control animals suggests that habituation to GrimACE is unnecessary, and that measurements can be repeated multiple times, ensuring standardized postoperative recovery monitoring.